eriodictyol has been researched along with Cell Transformation, Neoplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, H; Deng, Z; Fu, H; He, J; Li, C | 1 |
| Bode, AM; Cho, EJ; Cho, YY; Dong, Z; Kim, DJ; Lee, MH; Liu, K; Nadas, J; Pugliese, A; Yao, K; Zhang, J | 1 |
2 other study(ies) available for eriodictyol and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Eriodictyol inhibits breast carcinogenesis by targeting circ_0007503 and repressing PI3K/Akt pathway.
Topics: Animals; Breast Neoplasms; Carcinogens, Environmental; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Flavanones; Humans; MicroRNAs; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2022 |
Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.
Topics: Activating Transcription Factor 1; Animals; Cell Line; Cell Transformation, Neoplastic; Epidermal Growth Factor; Flavanones; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Structure, Tertiary; ras Proteins; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Transcriptional Activation | 2011 |